TEPOTINIB FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS: A US COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
Yang, M. [1 ]
Sachdev, R. [2 ]
Stargardter, M. [2 ]
Tosh, J. [3 ]
Vioix, H. [4 ]
机构：
[1] EMD Serono, Rockland, MA USA
[2] Evidera, Bethesda, MD USA
[3] Evidera, London, England
[4] Merck KGaA, Darmstadt, Germany
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE160
引用
收藏
页码：S365 / S365
页数：1
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF TEPOTINIB FOR PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER HARBORING METEX14 SKIPPING ALTERATIONS IN SPAIN
    Arriola, E.
    Batteson, R.
    Hook, E.
    Wheat, H.
    Vioix, H.
    Morros, M.
    Aguila, M.
    de los Santos Real, H.
    Soberon S, Fernandez
    Brines, M.
    Vazquez, S.
    VALUE IN HEALTH, 2023, 26 (06) : S86 - S86
  • [2] Budget impact of tepotinib in the treatment of adult patients with metastatic non-small cell lung cancer harboring METex14 skipping alterations in the United States
    Stargardter, Matthew
    McBride, Ali
    Tosh, Jon
    Sachdev, Rameet
    Yang, Mo
    Ambavane, Apoorva
    Mittal, Madhav
    Vioix, Helene
    Liu, Frank Xiaoqing
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 816 - 827
  • [3] Financial impact of tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer bearing METex14 skipping in the United States.
    Stargardter, Matthew
    Yang, Mo
    Tosh, Jon
    Ambavane, Apoorva
    Mittal, Madhav
    Vioix, Helene
    Liu, Frank Xiaoqing
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features
    Meng, Yan
    Zhou, Weiping
    Li, Chenping
    Zhou, Xiangjie
    Li, Xiao
    Li, Liang
    Fu, Qiye
    Huang, Jue
    Yue, Yali
    Shen, Xuguang
    Yang, Lijing
    Wang, Meiqing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [5] MODELING THE COST-EFFECTIVENESS IN A SUBPOPULATION: TEPOTINIB VERSUS CHEMOIMMUNOTHERAPY (C plus IO) IN UNTREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    Batteson, R.
    Vioix, H.
    Wheat, H.
    Battershill, W.
    VALUE IN HEALTH, 2023, 26 (12) : S122 - S122
  • [6] US health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib
    Paik, Paul K.
    Yang, Mo
    Knowles, Emma
    Hatswell, Anthony
    Vioix, Helene
    Liu, Frank Xiaoqing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [7] BUDGET IMPACT ANALYSIS OF TEPOTINIB IN ENGLAND FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    McLean, T.
    Alexopoulos, S.
    Hook, E.
    Batterson, R.
    Vioix, H.
    VALUE IN HEALTH, 2022, 25 (12) : S143 - S143
  • [8] Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non-Small Cell Lung Cancer Harboring Mesenchymal-Epithelial Transition Exon 14 Skipping
    Yang, Mo
    Vioix, Helene
    Sachdev, Rameet
    Stargardter, Matthew
    Tosh, Jon
    Pfeiffer, Boris M.
    Paik, Paul K.
    VALUE IN HEALTH, 2023, 26 (04) : 487 - 497
  • [9] Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
    Reinmuth, N.
    Popat, S.
    Paz-Ares, L.
    Knowles, E.
    Hatswell, A.
    McLean, T.
    Adrian, S.
    Gaumond, B.
    Vioix, H.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S985 - S986
  • [10] Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer
    Drusbosky, Leylah M.
    Dawar, Richa
    Rodriguez, Estelamari
    Ikpeazu, Chukwuemeka, V
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
12345